Loading…
Chinese biopharmaceutical company developing innovative small-molecule and biologic drugs, including therapies for fibrotic and inflammatory diseases.
Chinese biopharmaceutical company developing innovative small-molecule and biologic drugs, including therapies for fibrotic and inflammatory diseases.
Moat: narrow (IP / patents). Patent-protected pipeline of self-developed innovative drug candidates.
Headquarters: Suzhou, China · Employees: 1,055
Size Suzhou Zelgen Biopharmaceuticals (688266.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.60B, the 713th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥90.80 on 6 Nov 2026.
Performance Over six months the shares fell 12.7%, against +3.9% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 136.2% over the last twelve months (peer median +8.7%); the operating margin is 29.0% (peer median 12.7%).
Valuation It trades at 43.4× forward earnings against a peer median of 17.6× (2nd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +98%, so the hurdle is -78 pp: the price already allows for a slowdown.
Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.75B | CN¥804M | CN¥533M | CN¥386M | CN¥302M |
| Revenue growth | — | +51% | +38% | +28% | — |
| Gross profit | CN¥1.64B | CN¥682M | CN¥445M | CN¥302M | CN¥219M |
| EBITDA | n/a | -CN¥191M | -CN¥163M | -CN¥348M | -CN¥468M |
| Net income | CN¥569M | -CN¥163M | -CN¥138M | -CN¥279M | -CN¥457M |
| Free cash flow | CN¥829M | -CN¥201M | -CN¥42.6M | -CN¥283M | -CN¥452M |
| Capital expenditure | CN¥122M | CN¥181M | CN¥95.7M | CN¥62.6M | CN¥88.6M |
| Total debt | CN¥592M | CN¥1.15B | CN¥1.05B | CN¥886M | CN¥547M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals 688266.SS | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| InnoCare Pharma 9969.HK | $2.31B | -13% | +146% | 35% | 37.0× | 0.8% |
| HUTCHMED (China) 0013.HK | $2.58B | +9% | -9% | -6% | 40.8× | 49.9% |
| Ascentage Pharma Group International 6855.HK | $1.39B | -33% | +70% | -220% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688266.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.1% | +3.1% | 3rd lowest of 21 |
| 6-month return | -12.7% | +3.9% | 4th lowest of 20 |
| Distance from 52-week high | -43.2% | -22.0% | 2nd lowest of 21 |
| Revenue growth (TTM) | +136.2% | +8.7% | highest of 19 |
| Operating margin | 29.0% | 12.7% | highest of 17 |
| Forward P/E | 43.4× | 17.6× | 2nd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 20.5% | 1.5% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +98.4% | +5.9% | 2nd highest of 16 |
| Hurdle (Req g minus delivered) | -77.9 pp | -9.6 pp | 2nd least demanding of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 10.7× | -9.8% | +5.4% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% | +2.7% |